<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357810</url>
  </required_header>
  <id_info>
    <org_study_id>NU 14S03</org_study_id>
    <secondary_id>NCI-2014-02583</secondary_id>
    <secondary_id>STU00200112</secondary_id>
    <secondary_id>NU 14S03</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT02357810</nct_id>
  </id_info>
  <brief_title>Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas</brief_title>
  <official_title>A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if pazopanib when given in
      combination with topotecan can help to control sarcomas. The safety of this drug combination
      will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth
      of tumor cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine progression free rate at week 12 for patients with soft tissue sarcoma (STS)
      treated with pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan
      hydrochloride).

      SECONDARY OBJECTIVES:

      I. To determine the overall response rate for patients with STS treated with combination
      pazopanib and topotecan.

      II. To determine the clinical benefit rate (complete response [CR] + partial response [PR] +
      stable disease [SD]) for patients with STS treated with combination pazopanib and topotecan.

      III. To determine median progression-free rate (PFR) for patients with STS treated with
      combination pazopanib and topotecan.

      IV. To evaluate overall survival (OS) for patients with STS treated with combination
      pazopanib and topotecan.

      V. To assess safety and tolerability for patients treated with combination pazopanib and
      topotecan.

      VI. To estimate the PFR for patients with osteosarcoma treated with combination pazopanib and
      topotecan.

      VII. To estimate the PFR for patients with liposarcoma treated with combination pazopanib and
      topotecan.

      TERTIARY OBJECTIVES:

      I. To estimate the correlation of PFR and OS to levels of soluble vascular endothelial growth
      factor receptor 2 (sVEGFR2) and phosphatidylinositol-glycan biosynthesis class F (PIGF).

      OUTLINE:

      Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28 and
      topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence
      of disease progression or unacceptable toxicity or until discontinuation per patient
      preference or physician recommendation.

      After completion of study treatment, patients are followed up every 6 months for 2 or 5
      years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from enrollment to progression</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Progression defined as changes in RECIST 1.1 defined imaging, progression in non-target lesions as defined by RECIST 1.1, unequivocal clinical deterioration, or death from any cause. Will be estimated for each histologic group (STS, osteoscaroma, and liposarcoma) using Kaplan-Meier methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (CR + PR) per RECIST version 1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Response rates will be summarized by the observed proportion of patients with response, along with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (CR+ PR + SD) per RECIST version 1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Response rates will be summarized by the observed proportion of patients with response, along with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Time from the first dose of the study treatment until death from any cause, assessed up to 2 years</time_frame>
    <description>Will be estimated for each histologic group (STS, osteoscaroma, and liposarcoma) using Kaplan-Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>Toxicities will be tabulated and summarized by the number of patients experiencing each toxicity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in cytokine levels</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Verification of results of Sleijfer et al and to determine if there is an even earlier correlation that can be detected between levels of these cytokines and PFR as well as OS which may allow us to better predict treatment response early on in therapy.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Adult Liposarcoma</condition>
  <condition>Metastatic Liposarcoma</condition>
  <condition>Metastatic Osteosarcoma</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Liposarcoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Stage IV Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (pazopanib hydrochloride, topotecan hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pazopanib hydrochloride, topotecan hydrochloride)</arm_group_label>
    <other_name>GW786034B</other_name>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Topotecan Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pazopanib hydrochloride, topotecan hydrochloride)</arm_group_label>
    <other_name>Hycamtin Capsules</other_name>
    <other_name>Oral Hycamtin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (pazopanib hydrochloride, topotecan hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must provide written informed consent prior to performance of study-specific
             procedures or assessments and must be willing to comply with treatment and follow-up

          -  Patients must have a histologically confirmed diagnosis of:

               -  Metastatic soft tissue sarcomas (non-liposarcoma)

               -  Metastatic osteosarcoma

               -  Metastatic liposarcoma- high grade, de-differentiated, or myxoid Note: pathology
                  is not required to be reviewed at the treating institution; a copy of the
                  pathology report is sufficient for eligibility purposes

          -  Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0-1

          -  Patients must have measurable disease within 4 weeks prior to registration by Response
             Evaluation Criteria In Solid Tumors (RECIST) 1.1, defined as at least one lesion that
             can be accurately measured in at least one dimension (longest diameter to be recorded)
             as &gt;= 20 mm with conventional techniques or as &gt;= 10mm with spiral computed tomography
             (CT) scan

          -  Patients must have had a minimum of 1 and a maximum of 4 prior chemotherapy regimens
             for recurrent/metastatic disease; it will be up to the investigator to determine what
             constitutes a &quot;regimen&quot; in each case; the last dose of systemic therapy much have been
             given at least 4 weeks prior to initiation of therapy; patients receiving BCNU or
             mitomycin C must have received their last dose at least 6 weeks prior to initiation of
             therapy

          -  Patients with brain metastasis are eligible for participation only if they have been
             treated with definitive surgery or radiation (surgery Â± radiotherapy, radiosurgery, or
             gamma knife) and meet both of the following criteria: a) are asymptomatic and b) have
             no requirement for steroids or enzyme-inducing anticonvulsants in prior 12 week
             interval

          -  Absolute neutrophil count (ANC) &gt;= 1.5 X 10^9/L (tested within 7 days prior to
             Registration)

          -  Hemoglobin &gt;= 9 g/dL (5.6 mmol/L)

               -  Subjects may not have had a transfusion within 7 days of screening assessment

          -  Platelets &gt;= 100 X 10^9/L

               -  Subjects may not have had a transfusion within 7 days of screening assessment

          -  Prothrombin time (PT) or international normalized ratio (INR) =&lt; 1.2 X upper limit of
             normal (ULN)

               -  Subjects receiving anticoagulant therapy are eligible if their INR is stable and
                  within the recommended range for the desired level of anticoagulation

          -  Activated partial thromboplastin time (aPTT) =&lt; 1.2 X ULN

          -  Total bilirubin =&lt; 1.5 X ULN

          -  Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 X ULN

               -  Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of
                  normal) are not permitted

          -  Serum creatinine =&lt; 1.5 mg/dL (133 umol/L) or, if &gt; 1.5 mg/dL: calculated creatinine
             clearance (ClCR) &gt;= 30 mL/min to &gt;= 50 mL/min

          -  Urine protein to creatinine ratio (UPC) &lt; 1

               -  If UPC &gt;= 1, then a 24-hour urine protein must be assessed; subjects must have a
                  24-hour urine protein value &lt; 1 g to be eligible; use of urine dipstick for renal
                  function assessment is not acceptable

          -  Females of child-bearing potential (FOCBP) and males must agree to use adequate
             contraception prior to study entry, for the duration of study participation, and for
             30 days following completion of therapy; should a female patient become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately; Note: a FOCBP is any woman (regardless of sexual
             orientation, having undergone a tubal ligation, or remaining celibate by choice) who
             meets the following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy

               -  Has had menses at any time in the preceding 12 consecutive months (and therefore
                  has not been naturally postmenopausal for &gt; 12 months)

          -  FOCBP must have a negative pregnancy test within 7 days prior to registration on study

               -  Note: female patients who are lactating should discontinue nursing prior to the
                  first dose of study drug and should refrain from nursing throughout the treatment
                  period and for 14 days following the last dose of study drug

          -  Are able to swallow and retain oral tablets

        Exclusion Criteria:

          -  Patients with any of the following sarcoma histologic subtypes will not be eligible
             for participation:

               -  Alveolar soft-part sarcoma

               -  Chondrosarcoma

               -  Dermatofibrosarcoma

               -  Ewing sarcoma

               -  Gastrointestinal stromal tumor (GIST)

               -  Kaposi sarcoma (non-human immunodeficiency virus [HIV] and HIV related disease)

               -  Mixed mesodermal tumor/carcinosarcoma

               -  Low grade (grade 1) sarcomas

               -  Rhabdomyosarcoma (embryonal, alveolar, pleomorphic)

               -  Interdigitating dendritic sarcoma

               -  Giant cell tumor of the bone

          -  Patients must not have received prior treatment with pazopanib or topotecan

          -  Patients must not have an active secondary malignancy

          -  Prior malignancy, unless they have been disease-free for 3 years, or have a history of
             completely resected non-melanomatous skin carcinoma or successfully treated in situ
             carcinoma

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding including, but not limited to:

               -  Active peptic ulcer disease

               -  Known intraluminal metastatic lesion/s with risk of bleeding

               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
                  gastrointestinal conditions with increased risk of perforation

               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
                  abscess within 28 days prior to beginning study treatment

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product including, but not limited to:

               -  Malabsorption syndrome

               -  Major resection of the stomach or small bowel

          -  Corrected QT interval (QTc) &gt; 480 msecs using Bazett's formula

          -  History of any one or more of the following cardiovascular conditions within the past
             12 months:

               -  Cardiac angioplasty or stenting

               -  Myocardial infarction

               -  Unstable angina

               -  Coronary artery bypass graft surgery

               -  Symptomatic peripheral vascular disease

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association (NYHA)

          -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of &gt;= 140
             mmHg or diastolic blood pressure (DBP) of &gt;= 90mmHg Note: initiation or adjustment of
             antihypertensive medication(s) is permitted prior to study entry; following
             antihypertensive medication initiation or adjustment, blood pressure (BP) must be
             re-assessed three times at approximately 2-minute intervals; at least 24 hours must
             have elapsed between anti-hypertensive medication initiation or adjustment and BP
             measurement; these three values should be averaged to obtain the mean diastolic blood
             pressure and the mean systolic blood pressure; the mean SBP / DBP ratio must be &lt;
             140/90 mmHg (or 150/90 mm Hg, if this criterion deemed safe by principal investigator
             [PI] and the quality assurance monitor [QAM]) in order for a patient to be eligible
             for the study

          -  Patients with a history of cerebrovascular accident including transient ischemic
             attack (TIA), pulmonary embolism, or untreated deep venous thrombosis (DVT); patients
             with DVT must have received appropriate therapy for at least 6 months to be considered
             eligible

          -  Major surgery or trauma within 28 days prior to first dose of investigational product
             and/or presence of any non-healing wound, fracture, or ulcer (procedures such as
             catheter placement not considered to be major surgery)

          -  Evidence of active bleeding or bleeding diathesis

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
             increase the risk of pulmonary hemorrhage

               -  Large protruding endobronchial lesions in the main or lobar bronchi are excluded;
                  however, endobronchial lesions in the segmented bronchi are allowed

               -  Lesions extensively infiltrating the main or lobar bronchi are excluded; however,
                  minor infiltrations in the wall of the bronchi are allowed

          -  Recent hemoptysis (&gt;= 1/2 teaspoon [2.5 mL]) of red blood within 8 weeks before first
             dose of study drug

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with patient's safety, provision of informed consent, or compliance to
             study procedures

          -  Unable or unwilling to discontinue use of inducers and inhibitors of cytochrome P450
             (CYP450) listed for at least 14 days or five half-lives of a drug (whichever is
             longer) prior to the first dose of study drug and for the duration of the study;
             cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) substrates can be
             administered, but investigators will need to be aware of possible increased or
             decreased effectiveness of the non-study drug and this should be recorded in
             concomitant medications; breast cancer resistance protein (BCRP) and p-glycoprotein
             (PgP) inducers and inhibitors will be also prohibited

          -  Treatment with any of the following anti-cancer therapies:

               -  Radiation therapy, surgery or tumor embolization within 14 days prior to the
                  first dose of therapy

               -  Chemotherapy, immunotherapy, biologic therapy, investigational therapy or
                  hormonal therapy within 14 days or five half-lives of a drug (whichever is
                  longer) prior to the first dose of therapy

          -  Administration of any non-oncologic investigational drug within 30 days or 5
             half-lives whichever is longer prior to receiving the first dose of study treatment

          -  Any ongoing toxicity related to prior anti-cancer therapy that is &gt; grade 1 and/or
             that is progressing in severity (exceptions include alopecia, fatigue, and hematologic
             toxicities)

          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to pazopanib or topotecan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Agulnik</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>(312)695-1301</phone>
    <email>cancertrials@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly K. Curtis</last_name>
      <phone>480-301-8335</phone>
      <email>curtis.kelly1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly K. Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Attia</last_name>
      <phone>904-953-2558</phone>
      <email>attia.steven@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Attia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Agulnik</last_name>
      <phone>312-695-1222</phone>
      <email>m-agulnik@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed M. Milhem</last_name>
      <phone>319-356-2324</phone>
      <email>mohammed-milhem@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed M. Milhem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keith M. Skubitz</last_name>
      <phone>612-625-5109</phone>
      <email>skubi001@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Keith M. Skubitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott H. Okuno</last_name>
      <phone>507-284-4849</phone>
      <email>okuno.scott@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Scott H. Okuno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian A. Van Tine</last_name>
      <phone>314-747-8475</phone>
      <email>bvantine@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian A. Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas A. McFarland</last_name>
      <phone>608-265-3890</phone>
      <email>Thomas.mcfarland@uwmf.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas A. McFarland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

